Last reviewed · How we verify
NCT06049940
Safety and Immunogenicity of Tetanus Vaccine, Adsorbed in 18~44 Years Old Population
Phase 3 trial testing Investigational tetanus vaccine, adsorbed in Tetanus in 1,260 participants. Completed in 22 March 2024.
26 October 2023
Quick facts
| Lead sponsor | Sinovac Life Sciences Co., Ltd. |
|---|---|
| Phase | Phase 3 |
| Status | Completed |
| Study type | INTERVENTIONAL |
| Allocation | randomized |
| Design | parallel |
| Masking | quadruple |
| Primary purpose | prevention |
| Enrollment | 1,260 |
| Start date | 1 September 2023 |
| Primary completion | 26 October 2023 |
| Estimated completion | 22 March 2024 |
| Sites | 1 location across China |
Drugs / interventions tested
- Investigational tetanus vaccine, adsorbed — full drug profile →
- Control tetanus vaccine, adsorbed — full drug profile →
Conditions studied
- Tetanus — all drugs for Tetanus →
Sponsor
Sinovac Life Sciences Co., Ltd. — full company profile →
Who can join
Adults 18 to 44, any sex, with Tetanus. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
This is a randomized, double-blind, positive controlled design clinical trial of tetanus vaccine, adsorbed manufactured by Sinovac Life Sciences Co., Ltd.The purpose of this study is to evaluate the safety and immunogenicity of tetanus vaccine, adsorbed in 18\~44 years old population.
Publications & conference data
No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.
Verify or expand the search:
- PubMed search for NCT06049940
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Tetanus
Currently open trials in the same condition.
- NCT07358910 — Risk Assessment of Community Spread of Multiple Endemic Infectious Diseases in a One Health Perspective · recruiting
- NCT07107932 — A Registry： Siltartoxatug Injection for Tetanus Prophylaxis Following Injury · recruiting
- NCT06708286 — A Clinical Trials of Adsorbed Cell-free DPT Vaccine (Five-component) · Phase 2, PHASE3 · active not recruiting
- NCT06635798 — A Phase III Clinical Trail to Evaluate the Efficacy, Safety, Pharmacokinetics and Immunogenicity Characteristics of GR20 · Phase 3 · recruiting
- NCT06184542 — Phase I Clinical Trial of Diphtheria-Tetanus-acellular Pertussis Component Combined Vaccine · Phase 1 · recruiting
Other Sinovac Life Sciences Co., Ltd. trials
Trials by the same sponsor.
- NCT07374510 — Phase Ia Clinical Trial of Group ACYW135X Meningococcal Conjugate Vaccine · Phase 1 · not yet recruiting
- NCT06967272 — PhaseⅡClinical Trial of Oral Hexavalent Reassortant Rotavirus Attenuated Live Vaccine (Vero Cells) · Phase 2 · recruiting
- NCT06617715 — Clinical Trial of 13-Valent Pneumococcal Conjugate Vaccine · Phase 3 · recruiting
- NCT06550830 — Clinical Trial of PCV24 in Children Aged 2-17 Years · Phase 1 · completed
- NCT06474377 — Clinical Trial of PCV24 in Adults · Phase 1 · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06049940 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sinovac Life Sciences Co., Ltd.
- Last refreshed: 12 July 2024
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06049940.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing